You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰恩康(301263.SZ):華鉑凱盛的注射用紫杉醇聚合物膠束獲批臨牀試驗
格隆匯 02-07 18:33

格隆匯2月7日丨泰恩康(301263.SZ)公佈,公司全資子公司山東華鉑凱盛生物科技有限公司(簡稱“華鉑凱盛”)於近日收到國家藥品監督管理局簽發的《藥物臨牀試驗批准通知書》,同意華鉑凱盛提交的注射用紫杉醇聚合物膠束臨牀試驗的申請。

紫杉醇具備廣譜抗腫瘤潛力,是腫瘤化療的基礎藥物,廣泛用於乳腺癌、肺癌、卵巢癌、食管癌等多種惡性腫瘤疾病的治療。注射用紫杉醇聚合物膠束是抗腫瘤藥紫杉醇類產品中的新一代劑型,相較於其他紫杉醇劑型,注射用紫杉醇聚合物膠束在臨牀使用劑量大幅提升的情況下具有相對更好的安全性,用藥前無需任何抗過敏預處理,無需使用特殊輸液裝置,臨牀使用便捷。

2023年我國紫杉醇藥物行業市場規模達82.4億元,其中紫杉醇白蛋白約佔56.5%,紫杉醇脂質體約佔35.4%,紫杉醇注射液約佔8.1%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account